Mark A. Hellmann

1.6k total citations
44 papers, 961 citations indexed

About

Mark A. Hellmann is a scholar working on Neurology, Pathology and Forensic Medicine and Infectious Diseases. According to data from OpenAlex, Mark A. Hellmann has authored 44 papers receiving a total of 961 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Neurology, 17 papers in Pathology and Forensic Medicine and 8 papers in Infectious Diseases. Recurrent topics in Mark A. Hellmann's work include Peripheral Neuropathies and Disorders (16 papers), Multiple Sclerosis Research Studies (16 papers) and Myasthenia Gravis and Thymoma (8 papers). Mark A. Hellmann is often cited by papers focused on Peripheral Neuropathies and Disorders (16 papers), Multiple Sclerosis Research Studies (16 papers) and Myasthenia Gravis and Thymoma (8 papers). Mark A. Hellmann collaborates with scholars based in Israel, Germany and United States. Mark A. Hellmann's co-authors include Itay Lotan, Eldad Melamed, Israel Steiner, Ruth Djaldetti, Hadas Stiebel‐Kalish, Omer Bialer, Daniel Offen, Michael Bach, Hana Panet and Yael Barhum and has published in prestigious journals such as PLoS ONE, Neurology and Scientific Reports.

In The Last Decade

Mark A. Hellmann

40 papers receiving 940 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Hellmann Israel 16 616 355 167 152 135 44 961
Kimihiko Kaneko Japan 17 891 1.4× 838 2.4× 292 1.7× 92 0.6× 181 1.3× 65 1.2k
Mark B. Skeen United States 8 705 1.1× 193 0.5× 49 0.3× 240 1.6× 207 1.5× 21 1.1k
Shalom Haggiag Italy 17 260 0.4× 376 1.1× 85 0.5× 103 0.7× 93 0.7× 51 710
Kwang‐Kuk Kim South Korea 18 726 1.2× 338 1.0× 131 0.8× 152 1.0× 126 0.9× 47 961
Angelina Maria Martins Lino Brazil 9 540 0.9× 608 1.7× 275 1.6× 97 0.6× 89 0.7× 22 834
Annabel M. Ruiter Netherlands 7 882 1.4× 1.0k 2.9× 309 1.9× 91 0.6× 153 1.1× 12 1.4k
Aslı Kurne Türkiye 18 228 0.4× 284 0.8× 124 0.7× 65 0.4× 134 1.0× 60 746
Mark Woodhall United Kingdom 10 937 1.5× 854 2.4× 346 2.1× 80 0.5× 131 1.0× 14 1.2k
Hannah Pellkofer Germany 16 574 0.9× 606 1.7× 149 0.9× 80 0.5× 199 1.5× 24 1.1k
Tomomi Yonekawa Japan 16 443 0.7× 569 1.6× 269 1.6× 197 1.3× 212 1.6× 32 1.0k

Countries citing papers authored by Mark A. Hellmann

Since Specialization
Citations

This map shows the geographic impact of Mark A. Hellmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Hellmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Hellmann more than expected).

Fields of papers citing papers by Mark A. Hellmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Hellmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Hellmann. The network helps show where Mark A. Hellmann may publish in the future.

Co-authorship network of co-authors of Mark A. Hellmann

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Hellmann. A scholar is included among the top collaborators of Mark A. Hellmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Hellmann. Mark A. Hellmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ganelin‐Cohen, Esther, Adi Vaknin‐Dembinsky, Mark A. Hellmann, et al.. (2024). The effect of COVID‐19 vaccination on multiple sclerosis activity as reflected by MRI. Brain and Behavior. 14(7). e3587–e3587.
2.
Hellmann, Mark A., et al.. (2024). Association between clinical characteristics, acute steroid treatment and oligoclonal bands result in multiple sclerosis: A retrospective study. Multiple Sclerosis and Related Disorders. 85. 105554–105554. 1 indexed citations
3.
Milo, Ron, Elsebeth Staun-Ram, Dimitrios Karussis, et al.. (2022). Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses. Frontiers in Immunology. 13. 868915–868915. 26 indexed citations
4.
Lotan, Itay, et al.. (2022). Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis. Neuromuscular Disorders. 32(3). 230–235. 11 indexed citations
5.
Stiebel‐Kalish, Hadas, Kerstin Rubarth, Itay Lotan, et al.. (2022). Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis. Scientific Reports. 12(1). 21312–21312. 6 indexed citations
6.
Wilf‐Yarkoni, Adi, Itay Lotan, Israel Steiner, & Mark A. Hellmann. (2021). Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis. Journal of Neurology. 268(10). 3871–3877. 8 indexed citations
7.
Stiebel‐Kalish, Hadas, Mark A. Hellmann, Michael Mimouni, et al.. (2019). Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?. Neurology Neuroimmunology & Neuroinflammation. 6(4). e572–e572. 133 indexed citations
8.
Lotan, Itay, Mark A. Hellmann, Felix Benninger, Hadas Stiebel‐Kalish, & Israel Steiner. (2018). Recurrent optic neuritis – Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody disease. Journal of Neuroimmunology. 324. 115–118. 9 indexed citations
9.
Lotan, Itay, Mark A. Hellmann, Omer Bialer, et al.. (2018). Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation. Journal of Neurology. 265(9). 1985–1988. 22 indexed citations
10.
Hellmann, Mark A., et al.. (2014). Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. Journal of the Neurological Sciences. 344(1-2). 193–197. 26 indexed citations
11.
Hellmann, Mark A., et al.. (2013). Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. Journal of the Neurological Sciences. 338(1-2). 39–42. 27 indexed citations
12.
Hellmann, Mark A., et al.. (2012). Thoracic sensory level as a false localizing sign in cervical spinal cord and brain lesions. Clinical Neurology and Neurosurgery. 115(1). 54–56. 6 indexed citations
13.
Hellmann, Mark A., et al.. (2011). Sudden sensorineural hearing loss in multiple sclerosis: clinical course and possible pathogenesis. Acta Neurologica Scandinavica. 124(4). 245–249. 37 indexed citations
14.
Hellmann, Mark A., Eldad Melamed, Adam Steinmetz, & Ruth Djaldetti. (2010). Unilateral lower limb rest tremor is not necessarily a presenting symptom of Parkinson's disease. Movement Disorders. 25(7). 924–927. 10 indexed citations
15.
Hellmann, Mark A., Ruth Djaldetti, Zvi Israel, & Eldad Melamed. (2006). Effect of deep brain subthalamic stimulation on camptocormia and postural abnormalities in idiopathic Parkinson's disease. Movement Disorders. 21(11). 2008–2010. 47 indexed citations
16.
Hellmann, Mark A., Hana Panet, Yael Barhum, E. Melamed, & Daniel Offen. (2005). Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neuroscience Letters. 395(2). 124–128. 120 indexed citations
17.
Djaldetti, Ruth, Mark A. Hellmann, & Eldad Melamed. (2004). Bent knees and tiptoeing: Late manifestations of end‐stage Parkinson's disease. Movement Disorders. 19(11). 1325–1328. 22 indexed citations
18.
Hellmann, Mark A., et al.. (2003). Eosinophiles Granulom des Felsen- und Schläfenbeins: Fallbericht und Literaturübersicht. Laryngo-Rhino-Otologie. 82(4). 258–261. 1 indexed citations
19.
Hellmann, Mark A., et al.. (2003). Eosinophiles Granulom des Felsen- und Schläfenbeins. Laryngo-Rhino-Otologie. 82(4). 258–261. 5 indexed citations
20.
Hellmann, Mark A. & Eldad Melamed. (2002). Focal dystonia as the presenting sign in Creutzfeldt‐Jakob disease. Movement Disorders. 17(5). 1097–1098. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kimihiko Kaneko Breakdown of academic impact, for papers by Mark B. Skeen Breakdown of academic impact, for papers by Shalom Haggiag Breakdown of academic impact, for papers by Kwang‐Kuk Kim Breakdown of academic impact, for papers by Angelina Maria Martins Lino Breakdown of academic impact, for papers by Annabel M. Ruiter Breakdown of academic impact, for papers by Aslı Kurne Breakdown of academic impact, for papers by Mark Woodhall Breakdown of academic impact, for papers by Hannah Pellkofer Breakdown of academic impact, for papers by Tomomi Yonekawa
Rankless by CCL
2026